The European Union has launched an investigation into Swiss pharmaceutical powerhouses Roche and Novartis over concerns about potential antitrust violations in deals linked to former US President Donald Trump's administration.
EU Competition Probe
Brussels regulators are examining whether the two Basel-based companies engaged in anti-competitive practices during their COVID-19 treatment agreements with the Trump White House. The probe focuses on possible market manipulation and unfair pricing strategies that could have disadvantaged European healthcare systems.
Trump Connection Raises Eyebrows
Investigators are particularly interested in contracts signed during the height of the pandemic, when the Trump administration secured large quantities of experimental treatments. Sources suggest the EU suspects these deals may have created artificial shortages in European markets while driving up prices.
Industry Giants Respond
Both companies have issued statements denying any wrongdoing. Novartis emphasised its commitment to "ethical business practices and full compliance with all regulations", while Roche stated it is "fully cooperating with the investigation."
The outcome could have significant implications for pharmaceutical pricing across Europe and future pandemic preparedness strategies.
